Hyperbaric oxygenation improves redox control and reduces mortality in the acute phase of myocardial infarction in a rat model

Imagem de Miniatura
Arquivos
art_OLIVEIRA_Hyperbaric_oxygenation_improves_redox_control_and_reduces_mortality_2020.PDF (457.5 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
OLIVEIRA, Mario S.
ANTONIO, Ednei L.
SERRA, Andrey J.
SANTOS, Leonardo Dos
TUCCI, Paulo J. F.
Citação
MOLECULAR MEDICINE REPORTS, v.21, n.3, p.1431-1438, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Among the mechanisms of action of hyperbaric oxygenation (HBO), the chance of reducing injury by interfering with the mechanisms of redox homeostasis in the heart leads to the possibility of extending the period of viability of the myocardium at risk. This would benefit late interventions for reperfusion to the ischemic area. The objective of the present study was to investigate the changes in the redox system associated with HBO therapy maintained during the first hour after coronary occlusion in an acute myocardial infarction (MI) rat model. Surviving male rats (n=105) were randomly assigned to one of three groups: Sham (SH=26), myocardial infarction (MI=45) and infarction+hyperbaric therapy (HBO=34, 1 h at 2.5 atm). After 90 min of coronary occlusion, a sample of the heart was collected for western blot analysis of total protein levels of superoxide dismutase, catalase, peroxiredoxin and 3-nitrotyrosine. Glutathione was measured by enzyme-linked immunosorbent assay (ELISA). The detection of the superoxide radical anion was carried out by oxidation of dihydroethidium analyzed with confocal microscopy. The mortality rate of the MI group was significantly higher than that of the HBO group. No difference was noted in the myocardial infarction size. The oxidized/reduced glutathione ratio and peroxiredoxin were significantly higher in the SH and MI when compared to the HBO group. Superoxide dismutase enzymes and catalase were significantly higher in the HBO group compared to the MI and SH groups. 3-Nitrotyrosine and the superoxide radical were significantly lower in the HBO group compared to these in the MI and SH groups. These data demonstrated that hyperbaric oxygenation therapy decreased mortality by improving redox control in the hearts of rats in the acute phase of myocardial infarction.
Palavras-chave
myocardial infarction, hyperbaric oxygenation, redox control, mortality, oxidative stress, reactive oxygen species, antioxidant enzymes, nitration
URI
https://observatorio.fm.usp.br/handle/OPI/35401
Referências
  1. [Anonymous], 2019, IND HYP OX THER
  2. Aquilano K, 2003, J NEUROCHEM, V85, P1324, DOI 10.1046/j.1471-4159.2003.01783.x
  3. Baek JY, 2012, J BIOL CHEM, V287, P81, DOI 10.1074/jbc.M111.316711
  4. Bennett MH, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004818.pub4
  5. Bocci V, 2015, FRONT CHEM, V3, DOI 10.3389/fchem.2015.00004
  6. BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160
  7. Buettner GR, 2013, CELL BIOCHEM BIOPHYS, V67, P477, DOI 10.1007/s12013-011-9320-3
  8. Bulluck H, 2016, HEART, V102, P341, DOI 10.1136/heartjnl-2015-307855
  9. Cabigas BP, 2006, CARDIOVASC RES, V72, P143, DOI 10.1016/j.cardiores.2006.06.031
  10. Cao C, 2003, BIOCHEMISTRY-US, V42, P10348, DOI 10.1021/bi035023f
  11. Day AM, 2012, MOL CELL, V45, P398, DOI 10.1016/j.molcel.2011.11.027
  12. de Melo BL, 2016, FRONT PHYSIOL, V7, DOI 10.3339/fphys.2016.00541
  13. Dekleva M, 2004, AM HEART J, V148, DOI 10.1016/j.ahj.2004.03.031
  14. dos Santos L, 2008, BRAZ J MED BIOL RES, V41, P199, DOI 10.1590/S0100-879X2008005000007
  15. dos Santos L, 2009, CLIN EXP PHARMACOL P, V36, P594, DOI 10.1111/j.1440-1681.2008.05118.x
  16. Facundo HTF, 2006, FREE RADICAL BIO MED, V40, P469, DOI 10.1016/j.freeradbiomed.2005.08.041
  17. Fernandes DC, 2007, AM J PHYSIOL-CELL PH, V292, pC413, DOI 10.1152/ajpcell.00188.2006
  18. Frohlich GM, 2013, EUR HEART J, V34, P1714, DOI 10.1093/eurheartj/eht090
  19. Godman CA, 2010, ANN NY ACAD SCI, V1197, P178, DOI 10.1111/j.1749-6632.2009.05393.x
  20. Granger DN, 2015, REDOX BIOL, V6, P524, DOI 10.1016/j.redox.2015.08.020
  21. Hedstrom E, 2009, J CARDIOVASC MAGN R, V11, DOI 10.1186/1532-429X-11-38
  22. Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865
  23. Kanashiro RM, 2002, ANN THORAC SURG, V73, P1507, DOI 10.1016/S0003-4975(01)03416-6
  24. Kim CH, 2001, PFLUG ARCH EUR J PHY, V442, P519, DOI 10.1007/s004240100571
  25. KUHN LA, 1965, CIRC RES, V16, P499, DOI 10.1161/01.RES.16.6.499
  26. Leite PF, 2003, ARTERIOSCL THROM VAS, V23, P2197, DOI 10.1161/01.ATV.0000093980.46838.41
  27. Lundberg JO, 2008, NAT REV DRUG DISCOV, V7, DOI [10.1038/nrd2466, 10.1038/nrd2466-c2]
  28. Guadalupe NBM, 2015, INT J PHARMACOL, V11, P834, DOI 10.3923/ijp.2015.834.839
  29. Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298
  30. MOGELSON S, 1980, EUR J CARDIOL, V12, P135
  31. Omar SA, 2016, J INTERN MED, V279, P315, DOI 10.1111/joim.12441
  32. Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
  33. Poff AM, 2017, COMPR PHYSIOL, V7, P213, DOI 10.1002/cphy.c150032
  34. Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735
  35. Ristow M, 2011, FREE RADICAL BIO MED, V51, P327, DOI 10.1016/j.freeradbiomed.2011.05.010
  36. Shandling AH, 1997, AM HEART J, V134, P544, DOI 10.1016/S0002-8703(97)70093-0
  37. Soyer OS, 2006, J THEOR BIOL, V238, P416, DOI 10.1016/j.jtbi.2005.05.030
  38. Stavitsky Y, 1998, CARDIOLOGY, V90, P131, DOI 10.1159/000006832
  39. STERLING DL, 1993, CIRCULATION, V88, P1931, DOI 10.1161/01.CIR.88.4.1931
  40. Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
  41. Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf
  42. THOMAS MP, 1990, AM HEART J, V120, P791, DOI 10.1016/0002-8703(90)90194-3
  43. Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506
  44. Totzeck M., 2017, EXP MED BIOL, V982, P335, DOI 10.1007/978-3-319-55330-6_
  45. Vetterlein F, 2003, AM J PHYSIOL-HEART C, V285, pH755, DOI 10.1152/ajpheart.00269.2002
  46. Tavares AMV, 2012, EXP CLIN CARDIOL, V17, P263
  47. Vlahovic A, 2004, AM HEART J, V148, DOI 10.1016/j.ahj.2004.02.009
  48. WHALEN ROBERT E., 1968, PROGR CARDIOV DIS, V10, P575, DOI 10.1016/0033-0620(68)90007-8
  49. Yin XS, 2015, J CARDIOVASC PHARM T, V20, P428, DOI 10.1177/1074248414568196
  50. Yogaratnam JZ, 2010, CARDIOVASC REVASCULA, V11, P8, DOI 10.1016/j.carrev.2009.03.004
  51. Zhang Y, 2010, J MOL CELL CARDIOL, V49, P576, DOI 10.1016/j.yjmcc.2010.05.011
  52. Zhdanov G. G., 2001, Anesteziologiya i Reanimatologiya, P51

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - LIM/64
Artigos e Materiais de Revistas Científicas - ODS/03